Pain Mesotherapy vs
Corticosteroid Injection —
What the 2025 Evidence Says

“The conversation around corticosteroid injections has changed significantly in the last two years. The short-term pain relief is real — nobody disputes that. But the accumulating evidence on cartilage damage, tendon weakening, and joint deterioration is now impossible to ignore. Pain mesotherapy does not offer the same speed of relief. But it does not damage the structures it is trying to protect. That distinction matters enormously over a patient’s lifetime.” — Dr Philippe Hamida-Pisal, Medical Advisor, SoMUK — 22 Harley Street, London

A landmark Radiology study changes the conversation

In May 2025, a major study published in Radiology — one of the most respected clinical journals in the field — analysed data from the Osteoarthritis Initiative and produced findings that are reshaping how the medical community thinks about corticosteroid injections for musculoskeletal pain.

This is not an isolated finding. It confirms and extends a growing body of evidence that has been building for several years. Corticosteroid injections are effective at reducing inflammation and pain in the short term — typically 4–8 weeks — but may accelerate the very joint deterioration they are being used to manage.

4–8 weeks: typical duration of corticosteroid pain relief

2yr period over which significantly greater cartilage degradation was observed in corticosteroid group (Radiology 2025)

3–6 months: demonstrated pain relief duration with pain mesotherapy protocols (multiple RCTs)

---

What the literature actually shows — a balanced assessment

This is not a simple case of one treatment being universally superior. The evidence shows a nuanced picture that requires clinical judgement and patient-specific decision-making.

---

Direct comparison across key clinical parameters

	Corticosteroid Injection	Pain Mesotherapy
Speed of pain relief	Fast — 24–72 hours	Slower — 1–3 weeks for full effect
Duration of relief	Short — 4–8 weeks typically	Longer — 3–6 months with full course
Effect on cartilage	Catabolic risk — cartilage thinning with repeated use confirmed in 2025 Radiology study	No catabolic effect — does not damage joint structures
Effect on tendons	Risk of weakening and rupture with repeated injection, particularly rotator cuff	No tendon risk — intradermal delivery does not reach tendon level
Systemic side effects	Significant — blood sugar elevation, immune suppression, HPA axis effects with repeated use	Minimal — local effect only at therapeutic doses
Suitability for diabetics	Caution required — significant blood sugar elevation possible	Generally suitable — no glycaemic impact at clinical doses
Frequency limit	Maximum 3–4 per year per joint due to cumulative cartilage risk	No frequency limit — can be repeated as clinically indicated
Function scores (OA)	Significant short-term improvement; no advantage at 6 months vs placebo in some trials	Superior WOMAC and Oxford Knee Scale vs oral NSAIDs at 4 and 8 weeks (Farpour et al.)
Pre-surgical risk	Increased infection risk if given <3 months before joint replacement surgery	No known pre-surgical contraindication
Patient selection	Broad — but caution in diabetics, immunocompromised, and patients near surgery	Broader — suitable for many patients excluded from corticosteroid use

---

When to choose mesotherapy — and when not to

This is not an either/or decision in every case. The evidence suggests a sequenced approach that plays to the strengths of each modality.

Clinical situation	Recommended approach
Acute severe inflammatory pain requiring rapid relief	Corticosteroid injection may be appropriate as a bridge to longer-term management. Do not rely on it as the only intervention. Follow with mesotherapy once acute phase settles.
Chronic low back pain	Pain mesotherapy first line. RCT evidence (Costantino et al.) shows equivalent outcomes to systemic corticosteroid at 6 months without the systemic side effect burden.
Knee osteoarthritis (Grade 2–3)	Mesotherapy shows superior functional outcomes at 4–8 weeks vs oral NSAIDs. Avoid repeated corticosteroid injections given 2025 Radiology data on cartilage degradation. Consider combined mesotherapy + HA injection protocol.
Tendonitis and soft tissue pain	Mesotherapy preferred where tendon integrity is a concern. Corticosteroid injection near tendons carries rupture risk with repeat use. Mesotherapy for chronic tendonitis with repeated sessions shows sustained improvement.
Trigger point pain and myofascial syndrome	Mesotherapy with local anaesthetic (lidocaine) significantly outperforms dry needling. Multiple fluid types including NSAID solutions, vitamins, and local anaesthetics via mesotherapy are effective. Corticosteroid not the first choice.
Chronic neck pain	Mesotherapy shows VAS reduction of 2.26 points vs 0.79 for dry control (Paolucci et al.). Corticosteroid use in cervical spine requires specialist guidance. Mesotherapy is the appropriate non-specialist pain intervention.
Diabetic patients with musculoskeletal pain	Mesotherapy strongly preferred. Corticosteroid injections cause significant blood sugar elevation that may last 3–14 days and require medication adjustment. Mesotherapy carries no glycaemic risk at clinical doses.
Patients approaching joint replacement surgery	Avoid corticosteroid within 3 months of planned surgery due to infection risk. Mesotherapy for pain management in the pre-operative period is appropriate and does not carry the same post-operative risk.
Patients who have already had multiple corticosteroid injections	Transition to mesotherapy. Given the cumulative evidence on cartilage damage with repeated corticosteroid use, patients who have received 3+ injections in the same joint should be offered mesotherapy as the ongoing management approach.

---

Questions practitioners ask most

---